These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36291782)

  • 1. Dissecting the Immunological Profiles in
    Xu D; Liu S; Wu X; Marti TM; Dorn P; Schmid RA; Peng RW; Shu Y
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated NSD3 histone methylation activity drives squamous cell lung cancer.
    Yuan G; Flores NM; Hausmann S; Lofgren SM; Kharchenko V; Angulo-Ibanez M; Sengupta D; Lu X; Czaban I; Azhibek D; Vicent S; Fischle W; Jaremko M; Fang B; Wistuba II; Chua KF; Roth JA; Minna JD; Shao NY; Jaremko Ł; Mazur PK; Gozani O
    Nature; 2021 Feb; 590(7846):504-508. PubMed ID: 33536620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative multi-omic and machine learning approach for prognostic stratification and therapeutic targeting in lung squamous cell carcinoma.
    Zhang X; Zhang P; Ren Q; Li J; Lin H; Huang Y; Wang W
    Biofactors; 2025; 51(1):e2128. PubMed ID: 39391958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
    Kim A; Lim SM; Kim JH; Seo JS
    Front Immunol; 2021; 12():598671. PubMed ID: 33717076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of tumor microenvironment and identification of an immune signature to predict the prognosis and immunotherapeutic response in lung squamous cell carcinoma.
    Wu J; Xu C; Guan X; Ni D; Yang X; Yang Z; Wang M
    Ann Transl Med; 2021 Apr; 9(7):569. PubMed ID: 33987267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
    Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
    Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase.
    Rathert P
    Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
    Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
    Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for frequent concurrent DCUN1D1, FGFR1, BCL9 gene copy number amplification in squamous cell lung cancer.
    Chatziandreou I; Psaraki A; Paschidis K; Lazaris AC; Saetta AA
    Pathol Res Pract; 2021 May; 221():153412. PubMed ID: 33862557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospect of targeting lysine methyltransferase NSD3 for tumor therapy.
    Li D; Tian T; Ko CN; Yang C
    Pharmacol Res; 2023 Aug; 194():106839. PubMed ID: 37400043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression.
    Jeong GY; Park MK; Choi HJ; An HW; Park YU; Choi HJ; Park J; Kim HY; Son T; Lee H; Min KW; Oh YH; Lee JY; Kong G
    Cancer Res; 2021 Jan; 81(1):77-90. PubMed ID: 32967925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Hypoxia-Related Signature for Predicting Prognosis, Cellular Processes, Immune Microenvironment and Targeted Compounds in Lung Squamous Cell Carcinoma.
    Wu G; Zhu Z; Yang Z; He M; Ren K; Dong Y; Xue Q
    Int J Gen Med; 2022; 15():3991-4006. PubMed ID: 35437352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of histone lysine methyltransferase NSD3 in cancer.
    Han X; Piao L; Zhuang Q; Yuan X; Liu Z; He X
    Onco Targets Ther; 2018; 11():3847-3852. PubMed ID: 30013365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NSD3 in Cancer: Unraveling Methyltransferase-Dependent and Isoform-Specific Functions.
    Nuñez Y; Vera S; Baeza V; Gonzalez-Pecchi V
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel immunomodulators in lung squamous cell carcinoma based on transcriptomic data.
    Lin X; Li X; Ma B; Hang L
    Math Biosci Eng; 2022 Jan; 19(2):1843-1860. PubMed ID: 35135231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Clinical Prognostic Model for Metabolism-Related Genes in Squamous Lung Cancer and Correlation Analysis of Immune Microenvironment.
    Zhuang Z; Gao C
    Biomed Res Int; 2022; 2022():6962056. PubMed ID: 36110123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.